Overview

Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of Chinese herbal PSORI-CM01（YXBCM01） granule for stable plaque psoriasis, with blood stasis syndrome of Chinese Medicine.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Guangdong Provincial Hospital of Traditional Chinese Medicine
Criteria
Inclusion Criteria:

1. Stable plaque psoriasis, duration > 1 year.

2. Patients with Chinese medicine blood stasis syndrome. (2)18 to 65 years old, male or
female patient.

3. Mild psoriasis:3
4. Informed consent.

Exclusion Criteria:

1. Guttate psoriasis, inverse psoriasis or exclusively involves the face;

2. Acute progression of psoriasis, and erythroderma tendency.Not blood stasis
syndrome.Not stable psoriasis.

3. Pregnant, lactating, or which one plan to become pregnant in a year;

4. SAS（Self-rating Anxiety Scale）> 50 or SDS（Self-rating Depression Scale）> 53, or with
other psychiatric disorders;

5. With history of cardiovascular, respiratory, digestive, urinary, and hematologic
disease, which can't controlled through common treatment. Either with cancer,
infection, electrolyte imbalance, acid-base disturbance and calcium metabolic
disorder.

6. Allergic to any medicine or ingredients used in this study.

7. Participating other clinical trials or participated within 1 month.

8. Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic
therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12
weeks.

9. Patients need systemic treatment prescribed by doctors.